Lion Biotechnologies to Participate in Upcoming Investor Conferences
November 16 2015 - 8:00AM
Lion Biotechnologies, (Nasdaq:LBIO), a biotechnology company that
is developing novel cancer immunotherapies based on
tumor-infiltrating lymphocytes (TIL), today announced that
President and CEO Elma Hawkins, PhD, will participate in the
following upcoming investor conferences:
Jefferies Autumn 2015 Global Healthcare
Conference Date: Wednesday – Thursday, November 18-19,
2015 Location: The May Fair Hotel, London
Piper Jaffray 27th Annual Healthcare Conference
Date: Tuesday – Wednesday, December 1-2, 2015 Location: The New
York Palace Hotel, New York
Roth Immuno-Oncology Corporate Access Day Date:
Wednesday, December 16, 2015 Location: Park Hyatt, New York
About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology
company focused on the development of cancer immunotherapy products
for the treatment of various cancers. The company's lead product
candidate is an adoptive cell therapy using tumor-infiltrating
lymphocytes (TIL) for the treatment of patients with refractory
metastatic melanoma, and is based on a clinical Cooperative
Research and Development Agreement with the National Cancer
Institute. TIL therapy is also being evaluated in
physician-sponsored clinical trials at MD Anderson Cancer Center
and Moffitt Cancer Center. For more information, please visit
http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties described
in the Company's most recently filed quarterly report on Form 10-Q
and annual report on Form 10-K. Except as permitted by law, the
Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Investor Relations
The Trout Group
Elizabeth Broder
646-378-2945
ebroder@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024